Amrinone
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Amrinone".

Amrinone
Systematic (IUPAC) name
5-amino-3,4'-bipyridin-6(1H)-one
Identifiers
CAS number	60719-84-8
ATC code	C01CE01
PubChem	3698
Chemical data
Formula	C10H9N3O
Mol. mass	187.198 g/mol
Pharmacokinetic data
Bioavailability	n/a
Protein binding	10 to 49%
Metabolism	Hepatic
Half life	5 to 8 hours
Excretion	Renal (63%) and fecal (18%)
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	℞-only(US)
Routes	Intravenous

Amrinone (INN) or inamrinone (USAN, changed in 2000 to prevent confusion with amiodarone¹), trade name Inocor, is a type 3 pyridine phosphodiesterase inhibitor.²

It is used in the treatment of congestive heart failure.

Class

Cardiac inotrope.

Actions

Increases cardiac contractility, vasodilator. Acts by inhibiting the breakdown of both cAMP and cGMP

Indications

Short-term management of severe CHF.

Contraindications

Patients with history of hypersensitivity to the drug.

Precautions

May increase myocardial ischemia. Blood pressure, pulse, and EKG should be constantly monitored. Amrinone should only be diluted with normal saline or 1/2 normal saline; no dextrose solutions should be used. Furosemide should not be administered into an IV line delivering Amrinone.

Side effects

Reduction in platelets, nausea and vomiting cardiac arrhythmias.

Routes

IV bolus and infusion as described earlier.

Pediatric dosage

Safety in children has not been established

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.